These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 30719729)

  • 21. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
    Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H
    Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.
    Chasset F; Francès C; Barete S; Amoura Z; Arnaud L
    J Am Acad Dermatol; 2015 Apr; 72(4):634-9. PubMed ID: 25648824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus.
    Quelhas da Costa R; Aguirre-Alastuey ME; Isenberg DA; Saracino AM
    JAMA Dermatol; 2018 Dec; 154(12):1432-1440. PubMed ID: 30383114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The classification and diagnosis of cutaneous lupus erythematosus.
    Kuhn A; Landmann A
    J Autoimmun; 2014; 48-49():14-9. PubMed ID: 24486120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous lupus erythematosus: clinico-pathologic correlation.
    Filotico R; Mastrandrea V
    G Ital Dermatol Venereol; 2018 Apr; 153(2):216-229. PubMed ID: 29368845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.
    Vital EM; Wittmann M; Edward S; Md Yusof MY; MacIver H; Pease CT; Goodfield M; Emery P
    Arthritis Rheumatol; 2015 Jun; 67(6):1586-91. PubMed ID: 25707733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous Toll-like Receptor 9 Pre-Defines Hydroxychloroquine Dosage in Patients with Both Discoid and Subacute Lupus Erythematosus.
    Englert KA; Dyduch G; Kłosowicz A; Spałkowska M; Jaworek AK; Migacz-Gruszka K; Jarosz-Chudek A; Mercuri SR; Szpor J; Mazzoccoli G; Damiani G; Wojas-Pelc A
    Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38004071
    [No Abstract]   [Full Text] [Related]  

  • 28. Cutaneous Lupus Erythematosus in Children.
    Tsang V; Leung AKC; Lam JM
    Curr Pediatr Rev; 2021; 17(2):103-110. PubMed ID: 33655840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients.
    Wenzel J; Brähler S; Bauer R; Bieber T; Tüting T
    Br J Dermatol; 2005 Jul; 153(1):157-62. PubMed ID: 16029342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of
    Gardet A; Pellerin A; McCarl CA; Diwanji R; Wang W; Donaldson D; Franchimont N; Werth VP; Rabah D
    Front Immunol; 2019; 10():275. PubMed ID: 30846987
    [No Abstract]   [Full Text] [Related]  

  • 31. Cutaneous lupus erythematosus: diagnosis and management.
    Fabbri P; Cardinali C; Giomi B; Caproni M
    Am J Clin Dermatol; 2003; 4(7):449-65. PubMed ID: 12814335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cutaneous lupus erythematosus. Part 1: clinical manifestations and classification].
    Kuhn A; Gensch K; Ständer S; Bonsmann G
    Hautarzt; 2006 Mar; 57(3):251-67; quiz 268. PubMed ID: 16501922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus.
    Al-Rawi H; Meggitt SJ; Williams FM; Wahie S
    Lupus; 2018 Apr; 27(5):847-852. PubMed ID: 28862574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiological characteristics of patients with cutaneous lupus erythematosus.
    Avilés Izquierdo JA; Cano Martínez N; Lázaro Ochaita P
    Actas Dermosifiliogr; 2014; 105(1):69-73. PubMed ID: 24268922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus.
    Sigges J; Biazar C; Landmann A; Ruland V; Patsinakidis N; Amler S; Bonsmann G; Kuhn A;
    Autoimmun Rev; 2013 May; 12(7):694-702. PubMed ID: 23220353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. B Cell Signatures Distinguish Cutaneous Lupus Erythematosus Subtypes and the Presence of Systemic Disease Activity.
    Abernathy-Close L; Lazar S; Stannard J; Tsoi LC; Eddy S; Rizvi SM; Yee CM; Myers EM; Namas R; Lowe L; Reed TJ; Wen F; Gudjonsson JE; Kahlenberg JM; Berthier CC
    Front Immunol; 2021; 12():775353. PubMed ID: 34868043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous lupus erythematosus: update of therapeutic options part I.
    Kuhn A; Ruland V; Bonsmann G
    J Am Acad Dermatol; 2011 Dec; 65(6):e179-93. PubMed ID: 20739095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenetics of cutaneous lupus erythematosus.
    Hersh AO; Arkin LM; Prahalad S
    Curr Opin Pediatr; 2016 Aug; 28(4):470-5. PubMed ID: 27386968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic approach and treatment of cutaneous lupus erythematosus.
    Sticherling M; Bonsmann G; Kuhn A
    J Dtsch Dermatol Ges; 2008 Jan; 6(1):48-59. PubMed ID: 18190433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An update on clinical trials for cutaneous lupus erythematosus.
    Xie L; Lopes Almeida Gomes L; Stone CJ; Faden DF; Werth VP
    J Dermatol; 2024 Jul; 51(7):885-894. PubMed ID: 38491743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.